Advanced search
Publication Cover
Cancer Management and Research Volume 10, 2018 - Issue
Submit an article Journal homepage
89
Views
27
CrossRef citations to date
0
Altmetric
Original Research

The homogeneous and heterogeneous risk factors for the morbidity and prognosis of bone metastasis in patients with prostate cancer

Xu Guo1 Department of Bone and Soft Tissue Tumors, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, China;2 Department of Orthopedics, Cangzhou Central Hospital, Cangzhou, Hebei, China
,
Chao Zhang1 Department of Bone and Soft Tissue Tumors, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, China
,
Qi Guo1 Department of Bone and Soft Tissue Tumors, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, China;3 Department of Orthopedics, General Hospital of North China Petroleum Administration, Renqiu, Hebei, China
,
Yao Xu1 Department of Bone and Soft Tissue Tumors, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, China
,
Guowei Feng4 Department of Urology, Tianjin Key Laboratory of Breast Cancer Prevention and Therapy, Ministry of Education, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
,
Lili Li1 Department of Bone and Soft Tissue Tumors, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, China
,
Xiuxin Han1 Department of Bone and Soft Tissue Tumors, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, China
,
Feng Lu1 Department of Bone and Soft Tissue Tumors, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, China
,
Yulin Ma1 Department of Bone and Soft Tissue Tumors, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, China
,
Xin Wang5 Department of Epidemiology and Biostatistics, First Affiliated Hospital, Army Medical University, Chongqing, ChinaCorrespondence[email protected]
&
Guowen Wang1 Department of Bone and Soft Tissue Tumors, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, ChinaCorrespondence[email protected]
 show all
Pages 1639-1646 | Published online: 22 Jun 2018

References

  • TorreLABrayFSiegelRLFerlayJLortet-TieulentJJemalAGlobal cancer statistics, 2012CA Cancer J Clin20156528710825651787
  • RyersonABEhemanCRAltekruseSFAnnual Report to the Nation on the Status of Cancer, 1975–2012, featuring the increasing incidence of liver cancerCancer201612291312133726959385
  • XiaoWJZhuYZhuYDaiBYeDWEvaluation of clinical staging of the American Joint Committee on Cancer (eighth edition) for prostate cancerWorld J Urol201836576977429372356
  • BergKDThomsenFBMikkelsenMKImproved survival for patients with de novo metastatic prostate cancer in the last 20 yearsEur J Cancer201772202728024263
  • SteeleCBLiJHuangBWeirHKProstate cancer survival in the United States by race and stage (2001–2009): findings from the CONCORD-2 studyCancer2017123Suppl 245160517729205313
  • ManganoAMPacilioMIalongoPSemprebeneAVentroniGMangoLDosimetry-based consideration on remission and relapse after therapy with 223Ra-dichloride in castration-resistant prostate cancer (CRPC) with bone metastases. A case reportDiagnostics (Basel)201881 piiE1829495541
  • SaadFGleasonDMMurrayRA randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinomaJ Natl Cancer Inst200294191458146812359855
  • Network NCCNCCN Clinical Practice Guidelines in Oncology Prostate Cancer Version 22016 Available from: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdfAccessed March 15th, 2018
  • FonagerRFZachoHDLangkildeNCDiagnostic test accuracy study of 18F-sodium fluoride PET/CT, 99mTc-labelled diphosphonate SPECT/CT, and planar bone scintigraphy for diagnosis of bone metastases in newly diagnosed, high-risk prostate cancerAm J Nucl Med Mol Imaging20177521822729181269
  • HayesARBrungsDPavlakisNOsteoclast inhibitors to prevent bone metastases in men with high-risk, non-metastatic prostate cancer: a systematic review and meta-analysisPLoS One2018131e019145529370211
  • SanjayaIPMochtarCAUmbasRCorrelation between low Gleason score and prostate specific antigen levels with incidence of bone metastases in prostate cancer patients: when to omit bone scans?Asian Pac J Cancer Prev20131494973497624175761
  • ItoKKubotaYSuzukiKCorrelation of prostate-specific antigen before prostate cancer detection and clinicopathologic features: evaluation of mass screening populationsUrology200055570570910792085
  • ZamanMUFatimaNSajjadZMetastasis on bone scan with low prostate specific antigen (≤20 ng/ml) and Gleason’s score (<8) in newly diagnosed Pakistani males with prostate cancer: should we follow Western guidelines?Asian Pac J Cancer Prev20111261529153222126493
  • Rodríguez-AntolínAGómez-VeigaFAlvarez-OsorioJKFactors that predict the development of bone metastases due to prostate cancer: recommendations for follow-up and therapeutic optionsActas Urol Esp201438426326924156932
  • BrigantiAPassoniNFerrariMWhen to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification toolEur Urol201057455155820034730
  • AkazaHCarrollPCooperbergMRHinotsuSFifth Joint Meeting of J-CaP and CaPSURE: advancing the global understanding of prostate cancer and its managementJpn J Clin Oncol201242322623622217576
  • RudoniMAntoniniGFavroMThe clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancerEur J Nucl Med19952232072117540551
  • HaukaasSRoervikJHalvorsenOJFoellingMWhen is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prostate cancer?Br J Urol19977957707769158517
  • MartinAMCagneyDNCatalanoPBrain metastases in newly diagnosed breast cancer: a population-based studyJAMA Oncol2017381069107728301662

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.